`
`
`
`Sheehan & Associates, P.C.
`Spencer Sheehan
`60 Cuttermill Rd Ste 409
`Great Neck, NY 11021-3104
`Telephone: (516) 268-7080
`spencer@spencersheehan.com
`
`United States District Court
`Southern District of New York
`
`Luz Sanchez, individually and on behalf of
`all others similarly situated,
`
`Plaintiff,
`
`1:20-cv-10272
`
`- against -
`
`Class Action Complaint
`
`Avadim Health, Inc.,
`
`
`
`Defendant
`
`
`
`Plaintiff by attorneys alleges upon information and belief, except for allegations pertaining
`
`to plaintiff, which are based on personal knowledge:
`
`1. Avadim Health, Inc. (“defendant”) manufactures, distributes, markets, labels and
`
`sells Theraworx Muscle Cramp & Spasm Relief Foam (“Theraworx MCS” or “Product”), sold
`
`with a compression knee garment, with the active ingredient magnesium sulfate.
`
`2.
`
`The Product is sold to consumers from retail and online stores, and directly by
`
`Defendant, in containers of various sizes.
`
`3.
`
`The Product and its advertising contain numerous false, deceptive and misleading
`
`claims about its ability to provide pain relief.
`
`4.
`
`These claims were recently the subject of a decision by the National Advertising
`
`Division (NAD) which concluded the claims and marketing were not accurate and misleading.
`
`5.
`
`The Product is similar to external analgesic products which contain the active
`
`ingredients capsaicin, trolamine salicylate, and/or lidocaine.
`
`
`
`Case 1:20-cv-10272-JPC Document 1 Filed 12/06/20 Page 2 of 18
`
`6.
`
`The relevant FDA Monograph for these products limit the indications for use: “For
`
`the temporary relief of minor aches and pains of muscles and joints" [which may be followed by:
`
`"associated with" (select one or more of the following: ‘simple backache,’ ‘arthritis,’ ‘strains,’
`
`‘bruises,’ and ‘sprains.’).”
`
`7.
`
`The Monograph states, “the indications for OTC external analgesic drug products
`
`should emphasize that these products relieve only minor pain and have an action that is only
`
`temporary.”
`
`8. Defendant’s Product emphasizes its ability to provide pain relief of a more significant
`
`and enduring type than those covered by the Monograph, even though its active ingredient,
`
`magnesium sulfate, has not been reviewed or found to be generally recognized as safe or effective
`
`by the FDA to diagnose, treat, cure, prevent or mitigate any diseases or conditions.
`
`9.
`
`The front label representations include “Muscle Cramp and Spasm Relief,” “Prevents
`
`Cramps & Spasms,” “Releases Muscle Tightness,” “Reduces Muscle Soreness” and “Foam with
`
`Magnesium Sulfate.”
`
`2
`
`
`
`Case 1:20-cv-10272-JPC Document 1 Filed 12/06/20 Page 3 of 18
`
`10. Defendant’s online marketing proclaims: “Apply as Needed for Fast Relief – As soon
`
`
`
`as you feel a muscle cramp or spasm coming on, use Theraworx Relief to quickly release muscle
`
`tightness and reduce the soreness afterwards. There’s no limit to how many times you can apply it
`
`per day!”
`
`3
`
`
`
`Case 1:20-cv-10272-JPC Document 1 Filed 12/06/20 Page 4 of 18
`
`11. Other online marketing describes the Product as “Fast-Acting Muscle Cramp Relief.”
`
`
`
`12. The Product claims it “Prevents cramps and spams, Releases muscle tightness, [and]
`
`
`
`Relieves muscle soreness.”
`
`4
`
`
`
`Case 1:20-cv-10272-JPC Document 1 Filed 12/06/20 Page 5 of 18
`
`13. The representations on the packaging and website include:
`
`
`
`• “REDUCES the severity of symptoms associated with RLS [restless leg
`
`syndrome].”
`
`• “PREVENTS cramps and spasms when used daily.”
`
`• “[Q]uickly relieves muscle cramps and even prevents them when used daily.”
`
`• “Use Theraworx Relief twice daily (in the morning and before bedtime) to
`
`prevent nighttime muscle cramps and spasms, or three times daily if you also
`
`experience cramps or spasms during the day.”
`
`• “Theraworx Relief for Muscle Cramps and Spasms can be used as a companion
`
`product to manage the leg cramps associated with many important, commonly
`
`prescribed medications.”
`
`5
`
`
`
`Case 1:20-cv-10272-JPC Document 1 Filed 12/06/20 Page 6 of 18
`
`14. The Product’s marketing – on the packaging and in various media – touts its unique
`
`ability to deal with leg pain:
`
`• “Theraworx Relief is better than any product out there for leg cramps or spasms
`
`or even muscle soreness.”
`
`• “Nothing Else Like It on the Shelves.”
`
`• “Theraworx Relief is unique because it can be used prophylactically to prevent
`
`muscle spasms as well as to treat muscle spasms and cramps.”
`
`• “Before Theraworx Relief there wasn’t really a lot of options on the
`
`market…nothing really to get to the root of the problem.”
`
`• “And it works really quickly, like no other product I’ve ever seen on the market.
`
`And I love that there’s no side effects associated with it.”
`
`• “Non-opioid, non-centrally acting Theraworx Relief products offer real relief
`
`for those suffering from nocturnal cramps, symptoms associated with restless
`
`legs syndrome, and inflammation associated with arthritis or other joint
`
`conditions.”
`
`• “HEALTHCARE
`
`PROFESIONALS RECOMMEND THERAWORK
`
`RELIEF.”
`
`15. The side of the Product’s packaging states it is “Clinically proven to prevent and
`
`relieve muscle cramps and spasms, and symptoms associated with Restless Legs Syndrome.”
`
`6
`
`
`
`Case 1:20-cv-10272-JPC Document 1 Filed 12/06/20 Page 7 of 18
`
`16. The Product’s website contains numerous representations that it is “clinically
`
`
`
`proven” for the purpose which it is marketed:
`
`• “Clinically proven to prevent foot and leg cramps when used daily.”
`
`• “In multiple clinical studies, Theraworx Relief has been proven to: Provide fast
`
`acting relief of muscle cramps and spasms, as well as post-cramp soreness --
`
`most people get relief within minutes . . . [and] Reduce symptoms associated
`
`with restless leg syndrome (RLS).”
`
`• “In a research study including patients diagnosed with RLS, Theraworx Relief
`
`was shown to reduce symptoms commonly associated with and accompanying
`
`RLS, including muscle cramps and spasms.”
`
`7
`
`
`
`Case 1:20-cv-10272-JPC Document 1 Filed 12/06/20 Page 8 of 18
`
`• “In a clinical study, participants noticed a significant reduction in the frequency
`
`of their leg & foot cramps within the first 2 weeks of daily use.”
`
`• “All Theraworx Relief products are clinically proven safe and effective.”
`
`• “Clinically proven.”
`
`17. Defendant’s “clinically proven” claims mean it is promising that scientific evidence
`
`proves or “establishes” the truth of its claims.
`
`18. These types of claims are required to be proven with double-blind, randomized
`
`studies.
`
`19. Even the claims relating to efficacy that do not claim clinical proof are required by
`
`the FDA to be based on double-blind randomized evidence because the claims involve pain relief.
`
`20. A competent and reliable study must include blinding, randomization, and be
`
`appropriately-controlled, demonstrating that the treatment group experienced statistically
`
`significant difference to the 95% confidence level as compared to the control group, to mitigate
`
`bias and avoid placebo effects.
`
`21. Defendant has offered five studies in support of its claims, which fail to establish the
`
`Product is effective in support of its muscle cramp and spasm relief claims.1
`
`22. The studies focus on treating leg cramps/spasms and symptoms associated with RLS
`
`and nocturnal leg cramps.
`
`23. However, Defendant’s advertising is focused on relieving muscle cramps and spams
`
`more generally (i.e., everyday muscle cramps and spams).
`
`
`1 “The effect of Theraworx® Relief [MCS] on night-time cramps and associated symptoms.” “The Effect of a Topical
`Homeopathic Solution on Nocturnal Leg Cramps and Associated Symptoms,” “Nocturnal Cramps and Introduction
`of a Novel Topical Therapy,” “Effect of a Topical, Non-Systemic, Non-Centrally Acting Anti-Spasmodic on Division-
`One Athletes in Competition After Crossing Individual Muscle Spasm Threshold and Experiencing Exercise-
`Associated Muscle Cramps (EAMC)” and “Restless Leg Syndrome: The Efficacy of a Non-Systemic, Non-Centrally
`Acting Topical Treatment
`
`8
`
`
`
`Case 1:20-cv-10272-JPC Document 1 Filed 12/06/20 Page 9 of 18
`
`24. None of the studies evaluated the Product’s efficacy on “muscle soreness,” “post-
`
`cramp soreness,” “foot cramps,” “muscle tightness” or “leg cramps associated with many
`
`important, commonly prescribed medications.”
`
`25. None of the studies were designed to assess whether the Product prevents muscle
`
`cramps.
`
`26. None of the studies support the Product’s claims of “fast-acting muscle cramp and
`
`spasm relief” or “quick[] release [o]f muscle tightness,” since the time to relief was not measured.
`
`27.
`
`In fact, the time period of the studies were several weeks long, which is inconsistent
`
`with the “fast-acting” claims.
`
`28. The studies were not consistent with typical consumer usage based on the Product’s
`
`instructions, i.e., whether the product was used with the accompanying compression garment.
`
`29. The subject populations in many of the submitted studies were not relevant to the
`
`target audience of the challenged advertising – i.e., Division I college athletes.
`
`30. The studies failed to account for potential confounding factors.
`
`31. More than half of the studies were not blinded, which calls into question whether
`
`results were biased by either the technician or study participants.
`
`32. No evidence was presented about adequate controls or safeguards in the studies to
`
`prevent bias.
`
`33. Where one study had an adequate sample size, it otherwise failed to support the
`
`claims due to other reasons, such as not being randomized or blinded.
`
`34. There is no genuine scientific research and no scientifically reliable studies that
`
`support the extraordinary claims that the Product can provide the effects indicated.
`
`35. Defendant makes Product claims based on the recommendations of medical
`
`9
`
`
`
`Case 1:20-cv-10272-JPC Document 1 Filed 12/06/20 Page 10 of 18
`
`professionals: “HEALTHCARE PROFESSIONALS RECOMMEND THERAWORX RELIEF.”
`
`36. Such claims are significant to consumers, yet they are not supported by reliable
`
`evidence such as statistically significant surveys showing that a substantial portion of them
`
`recommend the product.
`
`37. The message to consumers is that the consensus among healthcare professionals is a
`
`recommendation of the Product.
`
`38. Defendant’s website makes misleading use of testimonials by pharmacists, in
`
`violation of the FTC’s Guides Concerning Use of Endorsements and Testimonials in Advertising
`
`(“FTC Endorsement Guides”).
`
`39. These endorsements include statements such as:
`
`• “Theraworx Relief is better than any product out there for leg cramps or spasms
`
`or even muscle soreness”
`
`• “Theraworx Relief is unique because it can be used prophylactically to prevent
`
`muscle spasms as well as to treat muscle spasms and cramps.”
`
`• “[b]efore Theraworx Relief there really weren’t a lot of options on the market...
`
`it was just some supplements that you could try or other over-the-counter
`
`medications that would be able to distract the nerve endings…nothing really to
`
`get to the root of the problem”
`
`• “it works really quickly, like no other product I’ve ever seen on the market.”
`
`• “I’ve never seen a product that works as well [as Theraworx Relief] for muscle
`
`cramps and muscle spasms.”
`
`• “Theraworx works so fast, usually within thirty seconds to a minute,”
`
`• “it can help prevent the actual muscle cramp by being applied before activity or
`
`10
`
`
`
`Case 1:20-cv-10272-JPC Document 1 Filed 12/06/20 Page 11 of 18
`
`before you have night cramps, before you go to bed at night.”
`
`40. Even if endorsements are the accurate sentiments of an endorser, §255.1(a) of the
`
`FTC Endorsement Guides states that “an endorsement may not convey any express or implied
`
`representation that would be deceptive if made directly by the advertiser.”
`
`41. Where the honest opinion of an endorser “would not be enough to substantiate a
`
`claim…the endorsement should also be supported by competent and reliable scientific evidence.”
`
`42. The endorsements are so broad that they reasonably can be understood to compare
`
`the Product to FDA-approved prescription medications.
`
`43. However, there is no reliable data showing that the Product exceeds all other
`
`competitors with respect to the attributes for which superiority is claimed
`
`44. Defendant’s claims are harmful and misleading because they cause consumers
`
`relying on their claims about the therapeutic benefit of the Product to forgo proven treatments.
`
`45. This results in painful and potentially serious underlying muscle or joint affliction
`
`and moderate to severe joint inflammation from arthritis or other causes going untreated or
`
`inadequately treated.
`
`46. Even if the Product has no harmful side effects, consumers are still harmed due to
`
`the failure to seek proven treatments and the economic deception through purchasing the Product
`
`based on false and misleading claims.
`
`47. Defendant’s branding, marketing and packaging of the Product is designed to – and
`
`does – deceive, mislead, and defraud plaintiff and consumers.
`
`48. Defendant sold more of the Product and at higher prices than it would have in the
`
`absence of this misconduct, resulting in additional profits at the expense of consumers.
`
`49. The value of the Product that plaintiff purchased and consumed was materially less
`
`11
`
`
`
`Case 1:20-cv-10272-JPC Document 1 Filed 12/06/20 Page 12 of 18
`
`than its value as represented by defendant.
`
`50. Had plaintiff and class members known the truth, they would not have bought the
`
`Product or would have paid less for it.
`
`51. As a result of the false and misleading labeling, the Product is an sold at a premium
`
`price, approximately no less than $18.99 per 7.1 OZ compared to other similar products
`
`represented in a non-misleading way, and higher than the price of the Product if it were represented
`
`in a non-misleading way.
`
`Jurisdiction and Venue
`
`52.
`
`Jurisdiction is proper pursuant to Class Action Fairness Act of 2005 (“CAFA”). 28
`
`U.S.C. § 1332(d)(2)
`
`53. Under CAFA, district courts have “original federal jurisdiction over class actions
`
`involving (1) an aggregate amount in controversy of at least $5,000,000; and (2) minimal
`
`diversity[.]” Gold v. New York Life Ins. Co., 730 F.3d 137, 141 (2d Cir. 2013).
`
`54. Plaintiff Luz Sanchez is a citizen of New York.
`
`55. Defendant Avadim Health, Inc. is a Delaware corporation with a principal place of
`
`business in Asheville, Buncombe County, North Carolina and is a citizen of North Carolina.
`
`56. “Minimal diversity” exists because plaintiff Luz Sanchez and defendant are citizens
`
`of different states.
`
`57. Upon information and belief, sales of the Product exceed $5 million during the
`
`applicable statutes of limitations, exclusive of interest and costs.
`
`58. Venue is proper a substantial part of the events or omissions giving rise to the claim
`
`occurred in this District.
`
`59. Plaintiff Tracey Jones purchased the Product on numerous occasions including but
`
`12
`
`
`
`Case 1:20-cv-10272-JPC Document 1 Filed 12/06/20 Page 13 of 18
`
`not limited to between August and November 2020, at stores including Rite Aid, 282 8th Ave New
`
`York, NY 10001.
`
`60. Plaintiff bought the Product at or exceeding the above-referenced price because she
`
`liked the product for its intended use and relied upon its “clinically proven” claims and other health
`
`claims, as described herein.
`
`61. Plaintiff was deceived by and relied upon the Product's deceptive labeling and
`
`marketing.
`
`62. Plaintiff would not have purchased the Product in the absence of Defendant’s
`
`misrepresentations and omissions or would have paid less for it.
`
`63. Plaintiff intends to, seeks to, and will purchase the Product again when she can do so
`
`with the assurance that Product's labels are consistent with the Product’s components.
`
`Class Allegations
`
`64. The class will consist of all purchasers of the Product who reside in New York during
`
`the applicable statutes of limitations.
`
`65. Plaintiff seeks class-wide injunctive relief based on Rule 23(b) in addition to a
`
`monetary relief class.
`
`66. Common questions of law or fact predominate and include whether defendant’s
`
`representations were and are misleading and if plaintiff and class members are entitled to damages.
`
`67. Plaintiff's claims and basis for relief are typical to other members because all were
`
`subjected to the same unfair and deceptive representations and actions.
`
`68. Plaintiff is an adequate representative because her interests do not conflict with other
`
`members.
`
`69. No individual inquiry is necessary since the focus is only on defendant’s practices
`
`13
`
`
`
`Case 1:20-cv-10272-JPC Document 1 Filed 12/06/20 Page 14 of 18
`
`and the class is definable and ascertainable.
`
`70.
`
`Individual actions would risk inconsistent results, be repetitive and are impractical
`
`to justify, as the claims are modest relative to the scope of the harm.
`
`71. Plaintiff's counsel is competent and experienced in complex class action litigation
`
`and intends to protect class members’ interests adequately and fairly.
`
`72. Plaintiff seeks class-wide injunctive relief because the practices continue.
`
`New York General Business Law (“GBL”) §§ 349 & 350
`(Consumer Protection Statutes)
`
`73. Plaintiff incorporates by reference all preceding paragraphs.
`
`74. Plaintiff and class members desired to purchase and consume products which were
`
`as described and marketed by defendant and expected by reasonable consumers, given the product
`
`type.
`
`75. Defendant’s acts and omissions are not unique to the parties and have a broader
`
`impact on the public.
`
`76. Defendant misrepresented the substantive, quantitative, qualitative, compositional
`
`and/or restorative attributes of the Product.
`
`77. The Product’s claims have a material bearing on price and consumer acceptance of
`
`the Product.
`
`78. Plaintiff relied on the statements, omissions and representations of defendant, and
`
`defendant knew or should have known the falsity of same.
`
`79. Plaintiff and class members would not have purchased the Product or paid as much
`
`if the true facts had been known, suffering damages.
`
`Negligent Misrepresentation
`
`80. Plaintiff incorporates by reference all preceding paragraphs.
`
`14
`
`
`
`Case 1:20-cv-10272-JPC Document 1 Filed 12/06/20 Page 15 of 18
`
`81. Defendant had a duty to disclose the absence of support for its claims and statements.
`
`82. This duty is based on defendant’s position as an entity which has held itself out as
`
`having special knowledge and experience in the production, service and/or sale of the product type.
`
`83. The representations took advantage of consumers’ cognitive shortcuts made at the
`
`point-of-sale and their trust in defendant, a well-known and respected brand or entity in this sector.
`
`84. Plaintiff and class members reasonably and justifiably relied on these negligent
`
`misrepresentations and omissions, which served to induce and did induce, the purchase of the
`
`Product.
`
`85. Plaintiff and class members would not have purchased the Product or paid as much
`
`if the true facts had been known, suffering damages.
`
`Breaches of Express Warranty, Implied Warranty of Merchantability and
`Magnuson Moss Warranty Act, 15 U.S.C. §§ 2301, et seq.
`
`86. Plaintiff incorporates by reference all preceding paragraphs.
`
`87. The Product was manufactured, labeled and sold by defendant or at its express
`
`directions and instructions, and warranted to plaintiff and class members that it possessed
`
`substantive, quality, restorative, and/or compositional attributes it did not.
`
`88. Defendant had a duty to disclose and/or provide non-deceptive descriptions and
`
`marketing of the Product.
`
`89. This duty is based, in part, on defendant’s position as one of the most recognized
`
`companies in the nation in this sector.
`
`90. Plaintiff provided or will provide notice to defendant, its agents, representatives, and
`
`their employees.
`
`91. Defendant received notice and should have been aware of these misrepresentations
`
`due to numerous complaints by consumers to its main office over the past several years regarding
`
`15
`
`
`
`Case 1:20-cv-10272-JPC Document 1 Filed 12/06/20 Page 16 of 18
`
`the Product, of the type described here.
`
`92. The Product did not conform to its affirmations of fact and promises due to
`
`defendant’s actions and were not merchantable because plaintiffs expected a product that was
`
`capable and proven to have the effects promised.
`
`93. Plaintiff and class members would not have purchased the Product or paid as much
`
`if the true facts had been known, suffering damages.
`
`Fraud
`
`94. Plaintiff incorporates by reference all preceding paragraphs.
`
`95. Defendant’s fraudulent intent is evinced by its failure to accurately market the
`
`Product on the packaging and in other media, when it knew its statements were neither true nor
`
`accurate and misled consumers.
`
`96. Plaintiff and class members would not have purchased the Product or paid as much
`
`if the true facts had been known, suffering damages.
`
`Unjust Enrichment
`
`97. Plaintiff incorporates by reference all preceding paragraphs.
`
`98. Defendant obtained benefits and monies because the Product was not as represented
`
`and expected, to the detriment and impoverishment of plaintiff and class members, who seek
`
`restitution and disgorgement of inequitably obtained profits.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Jury Demand and Prayer for Relief
`
`Plaintiff demands a jury trial on all issues.
`
` WHEREFORE, Plaintiff prays for judgment:
`
`1. Declaring this a proper class action, certifying plaintiff as representative and the
`
`undersigned as counsel for the class;
`
`16
`
`
`
`Case 1:20-cv-10272-JPC Document 1 Filed 12/06/20 Page 17 of 18
`
`2. Entering preliminary and permanent injunctive relief by directing defendant to correct the
`
`challenged practices to comply with the law;
`
`3. Injunctive relief to remove, correct and/or refrain from the challenged practices and
`
`representations, and restitution and disgorgement for members of the class pursuant to the
`
`applicable laws;
`
`4. Awarding monetary damages, statutory damages under the GBL and interest pursuant to
`
`the common law and other statutory claims;
`
`5. Awarding costs and expenses, including reasonable fees for plaintiff's attorneys and
`
`experts; and
`
`6. Other and further relief as the Court deems just and proper.
`
`Dated: December 6, 2020
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`Sheehan & Associates, P.C.
`/s/Spencer Sheehan
`Spencer Sheehan
`60 Cuttermill Rd Ste 409
`Great Neck NY 11021-3104
`Tel: (516) 268-7080
`Fax: (516) 234-7800
`spencer@spencersheehan.com
`E.D.N.Y. # SS-8533
`S.D.N.Y. # SS-2056
`
`
`17
`
`
`
`Case 1:20-cv-10272-JPC Document 1 Filed 12/06/20 Page 18 of 18
`
`1:20-cv-10272
`United States District Court
`Southern District of New York
`
`
`Luz Sanchez, individually and on behalf of all others similarly situated,
`
`
`
`
`
` - against -
`
`
`Avadim Health, Inc.,
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Plaintiff,
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` Defendant
`
`Class Action Complaint
`
`
`Sheehan & Associates, P.C.
`60 Cuttermill Rd Ste 409
`Great Neck NY 11021-3104
`Tel: (516) 268-7080
`Fax: (516) 234-7800
`
`
`
`
`
`
`Pursuant to 22 NYCRR 130-1.1, the undersigned, an attorney admitted to practice in the courts of
`New York State, certifies that, upon information, and belief, formed after an inquiry reasonable
`under the circumstances, the contentions contained in the annexed documents are not frivolous.
`
`Dated: December 6, 2020
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` /s/ Spencer Sheehan
` Spencer Sheehan
`
`
`
`
`
`
`
`
`
`
`
`
`